CLAIMS

1. Use of semaglutide in the manufacture of a medicament for the treatment of mild cognitive impairment or Alzheimer's disease~~A method for the treatment of dementia, wherein said method comprises administering the GLP-1 receptor agonist semaglutide to a subject in need thereof~~.

2. The use according to claim 1 wherein said medicament is for the treatment of mild cognitive impairment.

3. The use according to claim 1 wherein said medicament is for the treatment of Alzheimer's disease.

~~2. The method according to any one of the preceding claims, wherein treatment is reducing the risk of developing dementia.~~

~~3. The method according to any one of the preceding claims, wherein said dementia is all forms and all stages of dementia.~~

~~4. The method according to any one of the preceding claims, wherein said dementia is mild cognitive impairment or Alzheimer's disease.~~

4. Use of semaglutide in the manufacture of a medicament for the treatment of preclinical Alzheimer's disease, mild cognitive impairment of the Alzheimer's type, early onset familial Alzheimer's disease, or prodromal Alzheimer's disease.

5. The use according to claim 4, wherein treatment is reducing the risk of developing preclinical Alzheimer's disease, mild cognitive impairment of the Alzheimer's type, early onset familial Alzheimer's disease, or prodromal Alzheimer's disease.

6. The use according to any one of claims 1-3, wherein treatment is reducing the risk of developing mild cognitive impairment or Alzheimer's disease.

~~5. The method according to any one of the preceding claims, wherein said dementia is selected from the group consisting of preclinical Alzheimer's disease, mild cognitive~~

~~impairment of the Alzheimer's type, early onset familial Alzheimer's disease, and prodromal Alzheimer's disease.~~

~~6.~~7. The use~~method~~ according to any one of the preceding claims, wherein said GLP-1 receptor agonist is the sole pharmaceutically active ingredient administered to said subject.

~~7.~~8. The use~~method~~ according to any one of the preceding claims, wherein said GLP-1 receptor agonist is administered subcutaneously, such as in the form of a solution or suspension, and optionally in the form of a solution comprising at least 90% water and with pH in the range of 7.0-9.0.

~~8.~~9. The use~~method~~ according to any one of the preceding claims, wherein said GLP-1 receptor agonist is administered orally, such as in the form of a tablet.

~~9.~~10.The use~~method~~ according to the preceding claim, wherein said GLP-1 receptor agonist is administered in the form of a tablet comprising at least 30% (w/w) salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, such as SNAC.

~~10.~~11. The use~~method~~ according to any one of the preceding claims, wherein said administration of a GLP-1 receptor agonist is a chronic treatment in which semaglutide is administered for at least 12 months, such as for at least 16 months or at least 18 months.

12. Use of semaglutide in the manufacture of a pharmaceutical composition for treating mild cognitive impairment or Alzheimer's disease.

13. Use of semaglutide in the manufacture of a pharmaceutical composition for treating preclinical Alzheimer's disease, mild cognitive impairment of the Alzheimer's type, early onset familial Alzheimer's disease, or prodromal Alzheimer's disease

~~11. A method for the treatment of dementia, wherein said method comprises administering a GLP-1 receptor agonist to a human subject in need thereof, said subject has metabolic syndrome, and said GLP-1 receptor agonist comprises GLP-~~

~~1(7-37) (SEQ ID No: 1) optionally comprising one or more substitutions, deletions, additions and/or modifications.~~

~~12. The method according to the preceding claim, wherein said metabolic syndrome is one or more indications selected from the group consisting of pre-diabetes, diabetes, cardiovascular disease, obesity, and hypertension.~~

~~13. The method according to any one of the preceding claims, wherein said GLP-1 receptor agonist comprises a maximum of 10 amino acids which have been altered, e.g., by substitution, deletion, insertion and/or modification, compared to GLP-1(7-37) (SEQ ID No: 1).~~

~~14. The method according to any one of the preceding claims, wherein said GLP-1 receptor agonist is liraglutide or semaglutide.~~

~~15.~~14. The use~~method~~ according to any one of claims 12-13~~11-14~~, wherein said use~~method~~ is as defined in any one of claims 5-11~~1-10~~.